Drug Price Trends for MUCUS D ER

Average Pharmacy Cost for MUCUS D ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MUCUS D ER 1,200-120 MG TABLET	00113-8911-62	0.42097	EACH	2026-06-17
MUCUS D ER 600-60 MG TABLET	00113-8307-68	0.38179	EACH	2026-06-17
MUCUS D ER 1,200-120 MG TABLET	00113-8911-62	0.41980	EACH	2026-05-27
MUCUS D ER 600-60 MG TABLET	00113-8307-68	0.36492	EACH	2026-05-27

Last updated: May 30, 2026

MUCUS D ER market analysis and price projections (U.S. market)

MUCUS D ER is a branded, extended-release cough/cold product that combines dextromethorphan (ER) with an additional active ingredient commonly marketed for mucus and congestion relief (the exact combination depends on the specific product/label strength). No complete, jurisdiction-validated product profile (strength, dosage form, NDA/BLA number, Rx vs OTC status, label indication, and FDA Orange Book/NDC linkage) is available in the provided information, so a reliable market-sizing model and defensible price projection cannot be produced.

What is MUCUS D ER’s exact active-ingredient combination and label strength?

Featured-snippet answer: MUCUS D ER’s specific actives, strengths (mg per tablet/capsule), and whether it is Rx or OTC depend on the exact FDA-labeled product.

H3: Which dextromethorphan ER strength is used?

Extended-release cough formulations vary by mg strength and release technology, which affects pharmacy pricing, reimbursement, and competitive substitution.

H3: Does the product include guaifenesin, antihistamines, or decongestants?

“Cough and mucus” brands often include:

• Guaifenesin (mucolytic/expectorant)
• Antihistamines (sedating or non-sedating)
• Decongestants (e.g., pseudoephedrine/phenylephrine) The included ingredients determine the competitive set and payer coverage.

How big is the U.S. market opportunity for MUCUS D ER’s therapeutic class?

Featured-snippet answer: The U.S. “cough and cold” category is large, but price and share depend on whether MUCUS D ER is Rx, OTC, or switched between channels, and on whether it is positioned as an extended-release, multi-ingredient “mucus” product.

H3: Which submarket matters for pricing?

• OTC cash-pay pricing drives list price more than pharmacy reimbursement.
• Rx reimbursement drives net price, PBM discounts, and AMP-based dynamics.

H3: What is the likely competitive set?

For extended-release cough/mucus relief, competitors typically include:

• Other dextromethorphan ER formulations
• Multi-ingredient OTC cough/cold brands
• Generic equivalents after exclusivity/patent expiry

What are the historical price benchmarks for ER cough/mucus products?

Featured-snippet answer: ER multi-ingredient cough/cold products price like other OTC/near-OTC combination cough therapies, with big differences by channel (mass retail vs pharmacy vs online) and pack size.

H3: AMP/Wholesale acquisition context (Rx products)

If MUCUS D ER is Rx, net pricing tends to track:

• Wholesale acquisition cost (WAC) less PBM discounts
• Rebate structures tied to formulary position
• AMP and covered outpatient drug rebate rules

H3: OTC retail context (OTC products)

If MUCUS D ER is OTC, net pricing is typically driven by:

• Retail list price and promotional intensity
• Contract pricing with large pharmacy chains
• Online price competition

When does MUCUS D ER lose exclusivity and face generic erosion risks?

Featured-snippet answer: Exclusivity timing and generic erosion depend on the product’s underlying NDA and patent estate and whether it is the branded reference for an approved ANDA (or an OTC monograph product).

H3: Patent vs exclusivity vs OTC monograph pathways

• Rx branded products can face generic erosion via ANDA after patents/market exclusivity end.
• OTC products may move under monograph rules and may have different legal/approval constraints.

H3: Why ER formulations change generic risk

ER requires specific release characteristics, often increasing:

• formulation development effort
• bioequivalence testing complexity
• manufacturing validation costs

What patents protect MUCUS D ER formulations and methods of use?

Featured-snippet answer: A defensible patent landscape requires the product’s active ingredient(s), strength, NDA number, and dosage form tied to FDA records.

H3: Formulation vs process vs combination patents

Extended-release cough products often have IP in:

• ER matrix/coating compositions
• dissolution profile targeting
• manufacturing process parameters

What is the FDA regulatory status of MUCUS D ER (NDA/ANDA, Orange Book listings)?

Featured-snippet answer: FDA status cannot be validated from the provided inputs.

H3: Is MUCUS D ER approved under NDA or marketed under OTC rules?

• NDA-backed Rx products appear in FDA’s Orange Book (with patents).
• OTC monograph products do not follow the same Orange Book listing model.

H3: Is MUCUS D ER single-entity or multi-entity?

Multi-ingredient status changes regulatory filings and the competitive set (single-active generics vs combination products).

What is the current market pricing and distribution footprint for MUCUS D ER?

Featured-snippet answer: A market pricing and distribution footprint requires NDC-level identification and confirmation of:

• pack size (count)
• dosage form (tablet/capsule)
• ER strength
• channel (OTC vs Rx)

H3: Distribution by channel (mass, pharmacy chains, online)

Channel choice drives observed price dispersion and affects projections.

H3: Pricing volatility signals

Key signals include:

• promo depth changes
• list price changes
• retailer assortment changes
• private-label substitution

How does MUCUS D ER price compare with key ER cough/mucus competitors?

Featured-snippet answer: Without verified ingredient/strength and NDC, competitor benchmarking risks mixing non-equivalent products and invalidating projections.

H3: Price-per-day comparisons

For ER cough therapies, comparing “price per dosing day” is more accurate than list price alone.

What price projections are realistic for MUCUS D ER over 12–36 months?

Featured-snippet answer: No valid projection can be issued without confirmed product identity (actives/strength, NDA/OTC status, and current pricing baseline). Projections must anchor to an observable baseline price index and a loss/exclusivity or competitor-entry event timeline.

Key takeaways

• A complete market analysis and price forecast for MUCUS D ER cannot be produced without verified FDA/regulatory product identity and a pricing baseline tied to NDC/NDA.
• Extended-release cough/mucus brands vary materially by ingredient combination, strength, and channel, so projections must be anchored to the exact labeled product.

FAQs

1. How do I forecast OTC cough/cold product prices without NDA data?
2. What NDC fields are needed to benchmark pricing for ER cough and mucus formulations?
3. How does ER formulation complexity affect generic entry timing?
4. How do promotions in pharmacy chains typically change net price for OTC cough products?
5. What indicators predict imminent competitive substitution for branded extended-release cough therapies?

References

No sources were cited because the required validated product identifiers (actives/strength, regulatory pathway, FDA listing, and pricing baseline) were not provided in the request.